证券代码：688639 证券简称：华恒生物 公告编号：2025-045 安徽华恒生物科技股份有限公司 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 10 月 15 日（星期三）09:00-10:00 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 09 月 30 日（星期二）至 10 月 14 日（星期二）16:00 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ahb@ehuaheng.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 安徽华恒生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日发布公司 2025 年半年度报告。为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 10 月 15 日（星期三） 09:00-10:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 ...

Investment Rating - Industry investment rating: Overweight [1] Core Views - The chemical sector's overall performance ranked 17th this week, with a decline of 0.95%, underperforming the Shanghai Composite Index by 1.16 percentage points and the ChiNext Index by 2.91 percentage points [4][22] - The chemical industry is expected to continue its trend of differentiated growth in 2025, with recommendations to focus on synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] Summary by Sections Industry Performance - The chemical sector's performance this week was -0.95%, ranking it 17th among all sectors, while the top three performing sectors were power equipment, non-ferrous metals, and electronics [22][23] - The top three individual stocks in the chemical sector this week were Bluefeng Biochemical (61.16%), Shangwei New Materials (44.81%), and Huarsoft Technology (31.83%) [28] Key Industry Dynamics - A new plan for stable growth in the petrochemical industry was released by seven departments, aiming for an average annual growth of over 5% in value added from 2025 to 2026 [34] - The plan emphasizes the importance of technological innovation, digital empowerment, and environmental sustainability in the petrochemical sector [34] Investment Opportunities - Synthetic biology is highlighted as a key area for growth, with companies like Kasei Biotech and Huaheng Biological being recommended for investment [4][8] - The third-generation refrigerants are expected to enter a high prosperity cycle due to upcoming quota policies and stable demand growth from the air conditioning and cold chain markets [5] - The electronic specialty gases market presents significant domestic substitution opportunities, driven by rapid upgrades in the semiconductor and photovoltaic industries [6][8] - Light hydrocarbon chemicals are identified as a global trend, with a shift towards lighter raw materials expected to enhance the value of leading companies in this sector [8] - The COC polymer industry is accelerating its domestic industrialization process, with companies like AkzoNobel being recommended for attention [9] - Potash fertilizer prices are anticipated to rebound as supply tightens and demand increases due to rising agricultural planting intentions [10] - The MDI market is expected to improve due to oligopolistic supply dynamics and stable demand from polyurethane applications [12]

Investment Rating - The report maintains a "Positive" rating for the chemical industry [5][6][20] Core Insights - The petrochemical industry is expected to see stable growth due to the introduction of policies aimed at enhancing industry health and eliminating outdated capacity [5][6] - The demand for viscose filament is anticipated to tighten, leading to an upward trend in prices, while the grass herbicide market is expected to optimize its structure [5][6] - The global GDP growth is projected to remain at 2.8%, with stable oil demand despite some slowdown due to tariff policies [5][6] Industry Dynamics - Oil supply is expected to increase significantly, driven by non-OPEC production, while demand remains stable [5][6] - The coal market is anticipated to experience long-term price stabilization, with easing pressures on downstream sectors [5][6] - Natural gas exports from the U.S. are likely to accelerate, potentially lowering import costs [5][6] Chemical Sector Analysis - The report highlights that the viscose filament industry will see a supply-demand tightening, with a projected increase in operating rates from 84% to over 95% [5][6] - The grass herbicide market is set to address issues of low pricing and quality through upcoming industry meetings aimed at regulating competition [5][6] Investment Recommendations - The report suggests focusing on sectors benefiting from the "anti-involution" policy, including textiles, agriculture, and export-related chemicals [5][6] - Specific companies to watch include Xinxiang Chemical Fiber, Jilin Chemical Fiber, and Lier Chemical, which are expected to benefit from market dynamics [5][6][20] Key Company Valuations - The report provides a valuation table for key companies, indicating various ratings such as "Buy" and "Increase" for companies like Hailir Chemical, Yunnan Chemical, and Wanhu Chemical [20]

Group 1 - Core viewpoint: Huaheng Biological Technology Co., Ltd. has shown a significant stock price increase of 5.17%, reaching 34.60 CNY per share, with a total market capitalization of 8.654 billion CNY [1] - Company overview: Established on April 13, 2005, and listed on April 22, 2021, the company specializes in the research, production, and sales of amino acids and their derivatives [1] - Revenue composition: The main business revenue is derived from amino acid series (70.96%), followed by other products (20.96%), vitamin series (5.34%), and miscellaneous products (2.74%) [1] Group 2 - Fund holdings: Xinyin Fund has a significant position in Huaheng Biological, with its Xinyin Research Selected Stock A fund holding 41,100 shares, accounting for 2.42% of the fund's net value [2] - Fund performance: The Xinyin Research Selected Stock A fund has achieved a year-to-date return of 24.07% and a one-year return of 54.23%, ranking 2354 out of 4220 and 1673 out of 3824 in its category, respectively [2] - Fund manager: The fund is managed by Qiao Huaguo, who has been in the position for 1 year and 323 days, with the best and worst fund returns during his tenure being 60.78% and 22.15%, respectively [3]

证券代码：688639 证券简称：华恒生物 公告编号：2025-044 （二）股东大会召开的地点：合肥市高新区长安路197号公司A1会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ 注：截至股权登记日，公司总股本为250,115,693股，其中公司回购专户中的股份数量为496,600股，依 据《上市公司股份回购规则》，上市公司回购的股份不享有股东大会表决权，本次股东大会享有表决权 的股份总数为249,619,093股。 （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 安徽华恒生物科技股份有限公司2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025年9月23日 本次股东大会由公司董事会召集，董事长郭恒华女士主持，会议采用现场投票和网络投票相结合的表决 方式。本次股东大会的召集和召开程序、出席会议人员的资格和召集 ...

关于安徽华恒生物科技股份有限公司 安徽天禾律师事务所 2025 年第二次临时股东大会之法律意见书 天律意 2025 第 02525 号 根据《中华人民共和国公司法》(下称《公司法》)、《中华人民共和国证券 法》（下称《证券法》）的规定，以及贵公司（下称"公司"）与安徽天禾律师 事务所（下称"本所"）签订的《法律顾问合同》，本所律师出席公司 2025 年 第二次临时股东大会，并对本次股东大会相关事项进行了见证，出具本法律意见 书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用的原则，对本次股东大会所涉及的相关 事项进行了必要的核查和验证，核查了本所认为出具本法律意见书所需的相关文 件和资料。为出具本法律意见，本所律师审查了公司提供的以下文件： 1、《公司章程》； 2、公司 2025 年 9 月 4 日第四届董事会第二十三次会议决议和会议记录； 3、公司 2025 年 9 月 4 日第四届监事会第十八次会议决议和会议记录； 4、公司于 2025 年 9 月 5 日刊载于上海证券交易所 ...

证券代码：688639 证券简称：华恒生物 公告编号：2025-044 安徽华恒生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 23 日 （二） 股东大会召开的地点：合肥市高新区长安路 197 号公司 A1 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 147 | | --- | --- | | 普通股股东人数 | 147 | | 2、出席会议的股东所持有的表决权数量 | 102,927,398 | | 普通股股东所持有表决权数量 | 102,927,398 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 41.23 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 41.23 | 注：截 ...

Core Insights - The event "Biomanufacturing Leading Future Industrial Pattern" held in Changfeng, Hefei, is part of the 2025 World Manufacturing Conference, focusing on biomanufacturing as a key industry [1][3] - The Hefei Biomanufacturing Provincial Future Industry Pilot Zone is the only pilot zone in Anhui Province dedicated to life sciences [1][3] Group 1: Event Overview - The event emphasized the importance of biomanufacturing, discussing key common links and hot subfields, and aimed to promote industrial integration and cluster development [3] - The Hefei Biomanufacturing Provincial Future Industry Pilot Zone was officially approved in October 2024, with plans for the Hefei Synthetic Biomanufacturing Industrial Park [3] Group 2: Industry Development - The pilot zone has made significant progress in its first year, with major projects like the AI-driven biomanufacturing R&D base and microbial agent technology application base set to be completed soon [3] - The pilot zone currently hosts two listed biomanufacturing companies, with one more planning to go public next year, and five key enterprises are expected to achieve a combined output value of 4 billion yuan in 2024 [3][4] Group 3: Regional Focus - Anhui Province has established a comprehensive biomanufacturing industry system covering six sectors, with biopharmaceuticals, bio-foods, and bio-energy clusters each exceeding 10 billion yuan in scale [4] - Changfeng County aims to reach a biomanufacturing output value of 15 billion yuan by 2027 and over 30 billion yuan by 2030, with plans to establish four provincial-level innovation platforms and cultivate ten leading enterprises [5][7]

Core Viewpoint - The article emphasizes the significant policy support for the bio-manufacturing industry in China, highlighting the government's initiatives to promote green, intelligent, and high-end transformations in the light industry sector, particularly focusing on bio-based and biodegradable materials [2][3]. Policy Developments - On September 18, the Ministry of Industry and Information Technology, along with other departments, released the "Light Industry Stabilization Growth Work Plan (2025-2026)", which aims to enhance the quality and efficiency of traditional light industries while supporting emerging fields like bio-manufacturing [2]. - The plan outlines strategies to stabilize growth through consumption, investment, and exports, addressing structural contradictions in supply and demand [2]. Key Initiatives - The plan sets a target to promote 300 upgraded and innovative products and cultivate 10 specialty industrial zones with a scale exceeding 100 billion yuan by 2026 [3]. - It emphasizes optimizing supply, expanding consumption, and enhancing industrial ecology, with specific measures to accelerate technological breakthroughs in bio-manufacturing [3]. Green Development Focus - The plan promotes the establishment of a strict green standard system covering energy consumption, water usage, and pollutant emissions, encouraging the development of green factories in the light industry [4]. - It aims to drive innovation in bio-based materials and biodegradable products, supporting the transition to a circular economy in packaging and other sectors [4]. Recent Government Actions - The Ministry of Industry and Information Technology has issued multiple documents this year to support bio-based and bio-manufacturing initiatives, including the announcement of a list of 36 bio-manufacturing landmark products [5][6]. - The government is also fostering the establishment of pilot platforms for bio-manufacturing to facilitate industrial scale-up by 2027 [6][7]. Industry Events - The article mentions the upcoming "Non-grain Biomass High-Value Utilization Forum" scheduled for November 27-29 in Hangzhou, focusing on non-grain bio-based chemicals and materials [10].

Core Points - Liu Zhicheng, a core technical personnel of Anhui Huaheng Biological Technology Co., Ltd., has left the company due to personal reasons and will no longer hold any position within the company [2][3] - The company has signed a confidentiality and non-competition agreement with Liu Zhicheng, ensuring no disputes regarding patents or intellectual property, and the integrity of the company's intellectual property remains intact [2][6][7] - Liu Zhicheng has completed the handover of his work, and the company's production and technical research and development activities are proceeding normally, indicating that his departure will not have a substantial impact on the company's core competitiveness or ongoing operational capabilities [2][9] Details of Departure - Liu Zhicheng, born in 1985, is a Chinese national with a master's degree from Dalian University of Technology, and has held various positions within the company since April 2015 [4] - As of the announcement date, Liu Zhicheng directly held 22,197 shares of the company, accounting for 0.0089% of the total share capital [5] R&D and Intellectual Property - During his tenure, Liu Zhicheng participated in the company's technology research and development, and all intellectual property developed during his employment belongs to the company, with no disputes regarding ownership [6] - The company has a robust R&D system with 286 R&D personnel, representing 13.42% of the total workforce, indicating a well-structured team that does not rely on any single core technical personnel [8] Company Measures - The company has confirmed that all R&D projects are proceeding normally, and the existing core technical personnel and R&D team are capable of supporting future technological and innovative product development [10] - The company is committed to enhancing its R&D management mechanisms and optimizing its organizational structure to continuously improve its innovation capabilities and core competitiveness [10]